Insmed (NASDAQ:INSM) Price Target Raised to $110.00

Insmed (NASDAQ:INSM) had its price objective increased by UBS Group from $105.00 to $110.00 in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts have also weighed in on INSM. Wells Fargo & Company upped their price objective on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. Guggenheim restated a “buy” rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. JPMorgan Chase & Co. increased their price target on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Finally, Royal Bank of Canada started coverage on Insmed in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $100.00 price target on the stock. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, Insmed presently has an average rating of “Moderate Buy” and a consensus target price of $93.33.

Insmed Stock Down 0.2 %

Insmed stock opened at $74.89 on Thursday. The stock has a 50 day moving average of $75.66 and a two-hundred day moving average of $73.81. Insmed has a twelve month low of $21.92 and a twelve month high of $84.91. The stock has a market capitalization of $13.56 billion, a price-to-earnings ratio of -13.40 and a beta of 1.28. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. As a group, research analysts expect that Insmed will post -4.56 earnings per share for the current year.

Insider Buying and Selling at Insmed

In other Insmed news, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50. Following the transaction, the chief executive officer now owns 384,960 shares in the company, valued at $26,912,553.60. The trade was a 4.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Martina M.D. Flammer sold 6,172 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.64, for a total value of $392,786.08. Following the completion of the sale, the insider now directly owns 101,549 shares of the company’s stock, valued at $6,462,578.36. The trade was a 5.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock valued at $42,859,028 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.

Institutional Trading of Insmed

Hedge funds have recently made changes to their positions in the company. National Bank of Canada FI boosted its holdings in Insmed by 9.7% in the fourth quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 147 shares during the last quarter. CIBC Asset Management Inc boosted its stake in Insmed by 3.5% during the 3rd quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 149 shares during the last quarter. Abel Hall LLC increased its position in shares of Insmed by 4.7% in the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 151 shares during the last quarter. Snowden Capital Advisors LLC raised its stake in shares of Insmed by 2.5% in the 4th quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 158 shares in the last quarter. Finally, Commerce Bank lifted its position in shares of Insmed by 2.4% during the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 163 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.